Sydney, Australia, 01 December 2022:
Evotec partner Kazia Therapeutics Limited ("Kazia", NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer.

The publication, by Michael Paillasse and colleagues, summarises a large body of pre-clinical research conducted principally by scientists at Evotec SE and at the University Cancer Institute of Toulouse - Oncopole over a period of several years. It is now published in Cancer Research Communications, a recently-launched journal published by the American Association of Cancer Research ("AACR"). The data formed the basis of Kazia’s in-licensing of EVT801 from Evotec in 2021 and has since supported transition of the compound into an ongoing Phase I clinical trial in patients with advanced solid tumours.

The publication may be accessed via the journal website at
https://aacrjournals.org/cancerrescommun/article/2/11/1504/711325/Targeting-TumorAngiogenesis-with-the-Selective.

For further information, please follow this link to the full version of the press release from Kazia Therapeutics.